Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 2
2006 3
2007 2
2008 6
2009 4
2010 4
2011 4
2012 5
2013 4
2014 6
2015 7
2016 9
2017 12
2018 10
2019 19
2020 28
2021 23
2022 29
2023 16
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, Roberts C, Bishara M, Nice R, Lees CW, Sebastian S, Irving PM, Russell RK, McDonald TJ, Goodhand JR, Ahmad T, Kennedy NA; PANTS Consortium. Chanchlani N, et al. Among authors: irving pm. Lancet Gastroenterol Hepatol. 2024 Apr 16:S2468-1253(24)00044-X. doi: 10.1016/S2468-1253(24)00044-X. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 38640937
Defining predictors of responsiveness to advanced therapies in Crohn's disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine.
Wyatt NJ, Watson H, Anderson CA, Kennedy NA, Raine T, Ahmad T, Allerton D, Bardgett M, Clark E, Clewes D, Cotobal Martin C, Doona M, Doyle JA, Frith K, Hancock HC, Hart AL, Hildreth V, Irving PM, Iqbal S, Kennedy C, King A, Lawrence S, Lees CW, Lees R, Letchford L, Liddle T, Lindsay JO, Maier RH, Mansfield JC, Marchesi JR, McGregor N, McIntyre RE, Ostermayer J, Osunnuyi T, Powell N, Prescott NJ, Satsangi J, Sharma S, Shrestha T, Speight A, Strickland M, Wason JM, Whelan K, Wood R, Young GR, Zhang X, Parkes M, Stewart CJ, Jostins-Dean L, Lamb CA. Wyatt NJ, et al. Among authors: irving pm. BMJ Open. 2024 Apr 17;14(4):e073639. doi: 10.1136/bmjopen-2023-073639. BMJ Open. 2024. PMID: 38631839 Free PMC article.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A. Sands BE, et al. Among authors: irving pm. Inflamm Bowel Dis. 2024 Mar 9:izae024. doi: 10.1093/ibd/izae024. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38459910
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D'Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M; PROFILE Study Group. Noor NM, et al. Among authors: irving pm. Lancet Gastroenterol Hepatol. 2024 May;9(5):415-427. doi: 10.1016/S2468-1253(24)00034-7. Epub 2024 Feb 22. Lancet Gastroenterol Hepatol. 2024. PMID: 38402895 Free PMC article. Clinical Trial.
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.
Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C, Desoysa L, Dickins B, Din S, Emsley R, Foulds GA, Gribben J, Hawkey C, Irving PM, Kazmi M, Lee E, Loban A, Lobo A, Mahida Y, Moran GW, Papaioannou D, Parkes M, Peniket A, Pockley AG, Satsangi J, Subramanian S, Travis S, Turton E, Uttenthal B, Rutella S, Snowden JA. Lindsay JO, et al. Among authors: irving pm. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):333-345. doi: 10.1016/S2468-1253(23)00460-0. Epub 2024 Feb 7. Lancet Gastroenterol Hepatol. 2024. PMID: 38340759 Free article. Clinical Trial.
Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCT.
Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C, Desoysa L, Din S, Emsley R, Foulds GA, Gribben J, Hawkey C, Irving PM, Johnson P, Kazmi M, Lee E, Loban A, Lobo A, Mahida Y, Moran G, Papaioannou D, Parkes M, Peniket A, Pockley AG, Satsangi J, Subramanian S, Travis S, Turton E, Uttenthal B, Rutella S, Snowden JA. Lindsay JO, et al. Among authors: irving pm. Southampton (UK): National Institute for Health and Care Research; 2024 Jan. Southampton (UK): National Institute for Health and Care Research; 2024 Jan. PMID: 38408175 Free Books & Documents. Review.
Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource.
Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, Rimmer JE, De La Revilla Negro J, Pavey H, Pele L, Brooks J, Moran GW, Irving PM, Limdi JK, Lamb CA; UK IBD BioResource Investigators; Parkes M, Raine T. Kapizioni C, et al. Among authors: irving pm. J Crohns Colitis. 2023 Dec 2:jjad203. doi: 10.1093/ecco-jcc/jjad203. Online ahead of print. J Crohns Colitis. 2023. PMID: 38041850
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM. Allegretti JR, et al. Among authors: irving pm. J Gastroenterol Hepatol. 2024 Feb;39(2):264-271. doi: 10.1111/jgh.16386. Epub 2023 Nov 12. J Gastroenterol Hepatol. 2024. PMID: 37953548
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
Little RD, Swaine A, Reynolds R, Gibson DJ, Barrau M, D'Errico F, Hampal R, Sparrow MP, Roblin X, Irving PM, Ward MG. Little RD, et al. Among authors: irving pm. Inflamm Bowel Dis. 2023 Nov 10:izad248. doi: 10.1093/ibd/izad248. Online ahead of print. Inflamm Bowel Dis. 2023. PMID: 37951220
180 results